Latest Breaking News On - Sobi investor relations team - Page 19 : comparemela.com

Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint

Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairsConference call

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (1)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

/PRNewswire/ Sobi® and Sanofi today announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of.

United statesAnders ullmanThomas kudsk larsenPrnewswire sobiSobi investor relations teamAmunix pharmaceuticals incHead of research developmentMedical affairsChief medical officerEuropean commissionAmunix pharmaceuticalsNorth africaMiddle easternNorth americaMiddle eastSobi media

Sanofi - Aventis Groupe: Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO to redefine expectations for treatment of children ophilia A Paris, March 2, 2023. The XTEND-Kids phase

United statesFrance generalNordrhein westfalenEva schaefer jansenDennis riedlEvan berlandCorentine driancourtFelix lauscherKate conwayKarin knobeTarik elgoutniSandrine guendoulNathalie phamSally bainEuropean commissionDrug administration

FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB

/PRNewswire/ Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant),.

United statesLynn malecAnders ullmanEuropean commissionDrug administrationSobi investor relations teamCollege of wisconsinInvestigator at versiti blood research instituteHead of research developmentMedical directorComprehensive centerBleeding disordersAssociate investigatorVersiti blood research instituteAssociate professorMedical college